Altimmune, Inc.

Altimmune, Inc. Q3 2026 Earnings Recap

ALT Q3 2026 Published November 15, 2026

Get alerts when ALT reports next quarter

Set up alerts — free

Altimmune fell 16.6% after earnings, despite management’s positive framing. The transcript offers no new financial or clinical setback; the likely source of disappointment is the long wait for the pivotal PERFORMA readout, expected in 2029, with enrollment still ramping and ex-U.S. sites yet to activate.

Earnings Per Share Miss
$-0.15 vs $-0.13 est.
-13.2% surprise

Market Reaction

Post-Earnings -16.58%

See ALT alongside your other holdings

Add to your portfolio — free

Key Takeaways

  • PERFORMA Phase 3 is screening and dosing patients; the majority of planned U.S. sites are active, while ex-U.S. sites are expected to activate over the coming months.
  • The company anticipates PERFORMA’s 52-week data readout in 2029, leaving a lengthy timeline to a key MASH milestone.
  • Management said new 48-week IMPACT data highlighted antifibrotic activity; the study was published in *The Lancet* this week.
  • RECLAIM Phase 2 data in alcohol use disorder were presented as a late-breaking oral presentation; an FDA end-of-Phase 2 meeting is scheduled for next month.
  • Management cited estimates that 55%–94% of alcohol-related liver disease patients also meet criteria for alcohol use disorder, supporting its rationale for developing pemvidutide across both indications.
This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ALT on AllInvestView.

Get the Full Picture on ALT

Track Altimmune, Inc. in your portfolio with real-time analytics, dividend tracking, and more.

View ALT Analysis